<DOC>
	<DOCNO>NCT02452996</DOCNO>
	<brief_summary>In clinical study , safety tolerability GNbAC1 treatment MS patient evaluate healthy male volunteer .</brief_summary>
	<brief_title>Safety Study GNbAC1 Monoclonal Antibody Healthy Male Volunteers</brief_title>
	<detailed_description>The monoclonal antibody , GNbAC1 , target envelope protein ( Env ) human endogenous retrovirus ( HERV ) , also call multiple sclerosis associate retrovirus ( MSRV ) , consider critical factor development multiple sclerosis . This study ass pharmacokinetics , safety tolerability GNbAC1 follow single ascend dos ( 6 , 18 , 36 mg/kg ) administer via IV infusion .</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Healthy male subject determine past medical history , physical examination , vital sign , ECG laboratory test Screening confirm Day 1 sign inform consent . Aged 18 55 year , inclusive . History serious adverse reaction hypersensitivity drug . Presence history allergy require acute chronic treatment ( seasonal allergic rhinitis require treatment may tolerate ) . Need prescription medication within 15 day prior administration study drug and/or nonprescription medication within 7 day prior administration study drug anticipate need concomitant medication study . Participation clinical trial previous 3 month , i.e . completion previous trial plan first administration current trial . NOTE : Other protocoldefined Inclusion/Exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>GNbAC1</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Multiple Sclerosis Associated Retrovirus ( MSRV )</keyword>
	<keyword>MSRV-Envelope protein</keyword>
	<keyword>Monoclonal antibody</keyword>
</DOC>